Tag: link

AB “Ignitis grupė” (hereinafter – the Group) has announced a Group CEO selection, as the second term of the current CEO, Darius Maikštėnas, ends on February 28, 2027. According to the Law on Companies of the Republic of Lithuania, the same person may be appointed as the CEO of a state-owned company for no more than two consecutive terms.

AB “Ignitis grupė” (hereinafter – the Group) has announced a Group CEO selection, as the second term of the current CEO, Darius Maikštėnas, ends on February 28, 2027. According to the Law on Companies of the Republic of Lithuania, the same person may be appointed as the CEO of a state-owned company for no more than two consecutive terms.

NEW YORK, Aug. 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Novo Nordisk A/S (NYSE:NVO), Altimmune, Inc. (NASDAQ:ALT), SelectQuote, Inc. (NYSE:SLQT) and Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Washington, DC, Aug. 15, 2025 (GLOBE NEWSWIRE) --

Link to ThinkCareBelieve's Article:  https://thinkcarebelieve.blog/2025/08/15/week-30-of-america-in-the-trump-administration/?_thumbnail_id=32940

Compare the leading payday loan lenders in Seattle for 2025 and learn how borrowers with all credit backgrounds can access fast and secure short-term financing.

Public curiosity around nerve health is rising in 2025, with searches, podcasts, and social platforms highlighting natural approaches. Nerve Soothe enters this conversation with a formula designed around ingredient transparency, plant-based extracts, and consumer-driven expectations for wellness support.

Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years

A Media Snippet accompanying this announcement is available by clicking on this link.

BOSTON, MASSACHUSETTS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a pioneering clinical stage biotechnology company at the forefront of oxygen therapeutics, is proud to announce a major scientific milestone: the publication of Body Oxygen Homeostasis and Mitochondrial Function from Animal Models to Clinical Applications by Prof. Avraham Mayevsky, a key advisor to Bioxytran. This groundbreaking work dives deep into the science of oxygen regulation and mitochondrial health – revealing transformative insights that could redefine treatment for stroke, Alzheimer’s, and other critical conditions.

https://link.springer.com/book/10.1007/978-3-031-94113-9

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile

Virtual Events Include Investor Webinar and Presentation at Emerging Growth Conference 85

– Live video webcast on Thursday, August 21^st at 2:20 PM ET